https://anavex.com/news/anavex-life-sciences-to-present-at-the-7th-annual-evercore-isi-healthconx-conference-2024-2/ 2024-12-12T20:10:17+00:00 https://anavex.com/wp-content/uploads/2024/12/662-anavex-life-sciences-to-present-at-the-7th-annual-evercore-isi-healthconx-conference-2024.png https://anavex.com/news/anavex-life-sciences-to-report-new-long-term-oral-blarcamesine-phase-iib-iii-alzheimers-disease-data-at-j-p-morgan-2025-healthcare-conference/ 2024-12-12T20:10:47+00:00 https://anavex.com/wp-content/uploads/2024/12/716-anavex-life-sciences-to-report-new-long-term-oral-blarcamesine-phase-iib-iii-alzheimers-di675771c095c52 https://anavex.com/news/anavex-life-sciences-announces-submission-of-blarcamesine-maa-for-treatment-of-alzheimers-disease-to-ema-2/ 2024-12-12T20:10:54+00:00 https://anavex.com/wp-content/uploads/2024/12/664-anavex-life-sciences-announces-submission-of-blarcamesine-maa-for-treatment-of-alzheimers-67521df99dda6 https://anavex.com/news/anavex-life-sciences-announces-acceptance-of-peer-reviewed-manuscript-of-oral-blarcamesine-phase-iib-iii-data-in-a-reference-alzheimers-disease-journal-2/ 2024-12-12T20:10:59+00:00 https://anavex.com/wp-content/uploads/2024/12/666-anavex-life-sciences-announces-acceptance-of-peer-reviewed-manuscript-of-oral-blarcamesine67521dfadf3eb https://anavex.com/news/anavexs-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimers-trial-data-presented-at-ctad-conference-2024-2/ 2024-12-12T20:11:10+00:00 https://anavex.com/wp-content/uploads/2024/12/668-anavexs-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimers-trial-dat67521dfc0590c https://anavex.com/news/anavex-life-sciences-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-2024/ 2024-12-12T20:11:16+00:00 https://anavex.com/wp-content/uploads/2024/12/672-anavex-life-sciences-to-present-at-the-hc-wainwright-26th-annual-global-investment-confere67521e0086752 https://anavex.com/news/anavex-life-sciences-reports-fiscal-2024-third-quarter-financial-results-and-provides-business-update/ 2024-12-12T20:11:21+00:00 https://anavex.com/wp-content/uploads/2024/12/674-anavex-life-sciences-reports-fiscal-2024-third-quarter-financial-results-and-provides-busi67521e0198fdb https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2024-third-quarter-financial-results-on-tuesday-august-6-2024/ 2024-12-12T20:11:25+00:00 https://anavex.com/wp-content/uploads/2024/12/676-anavex-life-sciences-to-announce-fiscal-2024-third-quarter-financial-results-on-tuesday-au67521e02bc5b9 https://anavex.com/news/anavex-life-sciences-announces-translational-biomarker-data-for-anavex2-73-blarcamesine-in-fragile-x-syndrome-major-cause-of-autism-at-the-19th-nfxf-international-fragile-x-conference/ 2024-12-12T20:11:31+00:00 https://anavex.com/wp-content/uploads/2024/12/678-anavex-life-sciences-announces-translational-biomarker-data-for-anavex2-73-blarcamesine-in67521e05d1bb6 https://anavex.com/news/results-from-anavex-life-sciences-landmark-phase-iib-iii-trial-of-blarcamesine-presented-at-alzheimers-association-conference/ 2024-12-12T20:11:58+00:00 https://anavex.com/wp-content/uploads/2024/12/680-results-from-anavex-life-sciences-landmark-phase-iib-iii-trial-of-blarcamesine-presented-a67521e0a0f756 https://anavex.com/news/anavex-life-sciences-to-present-at-the-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference/ 2024-12-12T20:12:03+00:00 https://anavex.com/wp-content/uploads/2024/12/682-anavex-life-sciences-to-present-at-the-hc-wainwright-5th-annual-neuro-perspectives-virtual67521e0b32ea7 https://anavex.com/news/anavex-life-sciences-announces-expansion-of-leadership-team/ 2024-12-12T20:12:08+00:00 https://anavex.com/wp-content/uploads/2024/12/684-anavex-life-sciences-announces-expansion-of-leadership-team.png https://anavex.com/news/anavex-life-sciences-to-present-at-the-h-c-wainwright-2nd-bioconnect-investor-conference-at-nasdaq/ 2024-12-12T20:12:12+00:00 https://anavex.com/wp-content/uploads/2024/12/686-anavex-life-sciences-to-present-at-the-hc-wainwright-2nd-bioconnect-investor-conference-at67521e0d47ad5 https://anavex.com/news/anavex-life-sciences-reports-fiscal-2024-second-quarter-financial-results-and-provides-business-update/ 2024-12-12T20:12:17+00:00 https://anavex.com/wp-content/uploads/2024/12/688-anavex-life-sciences-reports-fiscal-2024-second-quarter-financial-results-and-provides-bus67521e0e57273 https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2024-second-quarter-financial-results-on-thursday-may-9th-2024/ 2024-12-12T20:12:21+00:00 https://anavex.com/wp-content/uploads/2024/12/690-anavex-life-sciences-to-announce-fiscal-2024-second-quarter-financial-results-on-thursday-67521e1622527 https://anavex.com/news/anavex-life-sciences-to-present-at-the-noble-capital-markets-virtual-healthcare-equity-conference/ 2024-12-12T20:12:26+00:00 https://anavex.com/wp-content/uploads/2024/12/692-anavex-life-sciences-to-present-at-the-noble-capital-markets-virtual-healthcare-equity-con67521e16e37e0 https://anavex.com/news/anavex-life-sciences-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference/ 2024-12-12T20:12:30+00:00 https://anavex.com/wp-content/uploads/2024/12/694-anavex-life-sciences-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference.png https://anavex.com/news/anavex-life-sciences-initiates-placebo-controlled-u-s-phase-2-clinical-trial-of-anavex3-71-in-schizophrenia/ 2024-12-12T20:12:36+00:00 https://anavex.com/wp-content/uploads/2024/12/696-anavex-life-sciences-initiates-placebo-controlled-us-phase-2-clinical-trial-of-anavex3-71-67521e18dd2f4 https://anavex.com/news/anavex-life-sciences-to-present-at-the-44th-annual-td-cowen-health-care-conference/ 2024-12-12T20:12:41+00:00 https://anavex.com/wp-content/uploads/2024/12/698-anavex-life-sciences-to-present-at-the-44th-annual-td-cowen-health-care-conference.png https://anavex.com/news/anavex-life-sciences-reports-fiscal-2024-first-quarter-financial-results-and-provides-business-update/ 2024-12-12T20:12:46+00:00 https://anavex.com/wp-content/uploads/2024/12/700-anavex-life-sciences-reports-fiscal-2024-first-quarter-financial-results-and-provides-busi67521e1a58373 https://anavex.com/news/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing-phase-2-study-of-anavex3-71-for-the-treatment-of-schizophrenia/ 2024-12-12T20:13:06+00:00 https://anavex.com/wp-content/uploads/2024/12/670-anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing-phas67521dfcebe6a https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2024-fourth-quarter-financial-results-on-monday-december-23-2024/ 2024-12-16T12:25:00+00:00 https://anavex.com/wp-content/uploads/2024/12/1214-anavex-life-sciences-to-announce-fiscal-2024-fourth-quarter-financial-results-on-monday-de67611d1479287 https://anavex.com/news/blarcamesine-receives-ema-filing-acceptance-for-treatment-of-alzheimers-disease/ 2024-12-23T11:55:00+00:00 https://anavex.com/wp-content/uploads/2024/12/1331-blarcamesine-receives-ema-filing-acceptance-for-treatment-of-alzheimers-disease.png https://anavex.com/news/anavex-life-sciences-reports-fiscal-2024-fourth-quarter-financial-results-and-provides-business-update/ 2024-12-23T12:25:00+00:00 https://anavex.com/wp-content/uploads/2024/12/1329-anavex-life-sciences-reports-fiscal-2024-fourth-quarter-financial-results-and-provides-bus676aae634d6ba https://anavex.com/news/anavex-life-sciences-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference/ 2025-01-06T12:25:00+00:00 https://anavex.com/wp-content/uploads/2025/01/1334-anavex-life-sciences-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference.png https://anavex.com/news/new-phase-iib-iii-clinical-data-demonstrates-over-three-years-of-continuous-treatment-with-oral-blarcamesine-to-significantly-benefit-early-alzheimers-disease-patients/ 2025-01-13T12:25:00+00:00 https://anavex.com/wp-content/uploads/2025/01/1384-new-phase-iib-iii-clinical-data-demonstrates-over-three-years-of-continuous-treatment-with678625b65c477 https://anavex.com/news/anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-iib-iii-data-in-the-journal-of-prevention-of-alzheimers-disease/ 2025-01-15T12:25:00+00:00 https://anavex.com/wp-content/uploads/2025/01/1386-anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-iib-ii6788fceb61f8e https://anavex.com/news/anavex-life-sciences-announces-issuance-of-blarcamesine-anavex2-73-composition-of-matter-u-s-patent-expanding-its-intellectual-property-portfolio/ 2025-01-27T12:25:00+00:00 https://anavex.com/wp-content/uploads/2025/01/1496-anavex-life-sciences-announces-issuance-of-blarcamesine-anavex2-73-composition-of-matter-u67981848c9027 https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2025-first-quarter-financial-results-on-wednesday-february-12-2025/ 2025-02-05T12:25:00+00:00 https://anavex.com/wp-content/uploads/2025/02/1498-anavex-life-sciences-to-announce-fiscal-2025-first-quarter-financial-results-on-wednesday-67a49e9b1ccdd https://anavex.com/news/anavex-life-sciences-reports-fiscal-2025-first-quarter-financial-results-and-provides-business-update/ 2025-02-12T12:25:00+00:00 https://anavex.com/wp-content/uploads/2025/02/1500-anavex-life-sciences-reports-fiscal-2025-first-quarter-financial-results-and-provides-busi67ad22290dd59 https://anavex.com/news/anavex-life-sciences-to-present-at-the-45th-annual-td-cowen-health-care-conference/ 2025-02-24T12:25:00+00:00 https://anavex.com/wp-content/uploads/2025/02/1503-anavex-life-sciences-to-present-at-the-45th-annual-td-cowen-health-care-conference.png https://anavex.com/news/anavex-life-sciences-to-present-at-the-24th-annual-needham-virtual-healthcare-conference/ 2025-12-08T19:24:19+00:00 https://anavex.com/wp-content/uploads/2025/04/1506-anavex-life-sciences-to-present-at-the-24th-annual-needham-virtual-healthcare-conference.png https://anavex.com/news/anavex-life-sciences-announces-positive-up-to-4-years-oral-blarcamesine-results-from-phase-iib-iii-open-label-extension-trial-in-early-alzheimers-disease/ 2025-12-08T19:24:58+00:00 https://anavex.com/wp-content/uploads/2025/04/1508-anavex-life-sciences-announces-positive-up-to-4-years-oral-blarcamesine-results-from-phase67f278c252ff9 https://anavex.com/news/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east/ 2025-12-08T19:26:34+00:00 https://anavex.com/wp-content/uploads/2025/04/1510-anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-680763711aed2 https://anavex.com/news/anavex-life-sciences-announces-appointment-of-dr-audrey-gabelle-md-phd-to-the-scientific-advisory-board/ 2025-12-08T19:33:10+00:00 https://anavex.com/wp-content/uploads/2025/04/1512-anavex-life-sciences-announces-appointment-of-dr-audrey-gabelle-md-phd-to-the-scientific-a680a41b492cd4 https://anavex.com/news/anavex-life-sciences-to-participate-in-the-citizens-life-sciences-conference/ 2025-12-08T19:34:14+00:00 https://anavex.com/wp-content/uploads/2025/04/1514-anavex-life-sciences-to-participate-in-the-citizens-life-sciences-conference.png https://anavex.com/news/anavex-life-sciences-announces-full-enrollment-of-phase-2-study-of-anavex3-71-for-the-treatment-of-schizophrenia/ 2025-12-08T19:35:33+00:00 https://anavex.com/wp-content/uploads/2025/05/1516-anavex-life-sciences-announces-full-enrollment-of-phase-2-study-of-anavex3-71-for-the-trea6814131204154 https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2025-second-quarter-financial-results-on-tuesday-may-13-2025/ 2025-12-08T19:36:28+00:00 https://anavex.com/wp-content/uploads/2025/05/1518-anavex-life-sciences-to-announce-fiscal-2025-second-quarter-financial-results-on-tuesday-m681af0f2c2bfa https://anavex.com/news/anavex-life-sciences-reports-fiscal-2025-second-quarter-financial-results-and-provides-business-update/ 2025-12-08T19:37:53+00:00 https://anavex.com/wp-content/uploads/2025/05/1520-anavex-life-sciences-reports-fiscal-2025-second-quarter-financial-results-and-provides-bus6823556f0bfef https://anavex.com/wp-content/uploads/2025/05/79bcf7_46f2d02ea333448285684f170466e4c6mv2.png https://anavex.com/wp-content/uploads/2025/05/79bcf7_af1e4f708b9b448699a71dfa23cc28a6mv2.png https://anavex.com/wp-content/uploads/2025/05/79bcf7_f18ffa6acbf647f2a4812c4ad7f543abmv2.png https://anavex.com/news/anavex-life-sciences-to-participate-at-upcoming-healthcare-conferences/ 2025-12-08T19:39:35+00:00 https://anavex.com/wp-content/uploads/2025/05/1522-anavex-life-sciences-to-participate-at-upcoming-healthcare-conferences.png https://anavex.com/news/anavex-life-sciences-announces-positive-precision-medicine-results-from-up-to-4-years-of-oral-blarcamesine-treatment-in-phase-iib-iii-open-label-extension-trial-in-early-alzheimers-disease/ 2025-12-08T19:41:12+00:00 https://anavex.com/wp-content/uploads/2025/08/1527-anavex-life-sciences-announces-positive-precision-medicine-results-from-up-to-4-years688c8ab15092a.png https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2025-third-quarter-financial-results-on-tuesday-august-12-2025/ 2025-12-08T19:46:01+00:00 https://anavex.com/wp-content/uploads/2025/08/1529-anavex-life-sciences-to-announce-fiscal-2025-third-quarter-financial-results-on-tuesd689208f6a287e.png https://anavex.com/news/anavex-life-sciences-reports-fiscal-2025-third-quarter-financial-results-and-provides-business-update/ 2025-12-08T19:48:54+00:00 https://anavex.com/wp-content/uploads/2025/08/1531-anavex-life-sciences-reports-fiscal-2025-third-quarter-financial-results-and-provides689b983c984b6.png https://anavex.com/wp-content/uploads/2025/08/191fc6_5da64625c82649caabaa4f6f6b30ebc9mv2.webp https://anavex.com/wp-content/uploads/2025/08/191fc6_bff8dbe6cf4b4ce3905a798dee5b18ebmv2.webp https://anavex.com/wp-content/uploads/2025/08/191fc6_ccd679e6639a4307b3ff9e44ff4834c6mv2.webp https://anavex.com/news/anavex-life-sciences-reports-new-publication-in-medical-journal-highlighting-the-established-precise-autophagy-mechanism-with-blarcamesine/ 2025-12-08T19:50:17+00:00 https://anavex.com/wp-content/uploads/2025/08/1535-anavex-life-sciences-reports-new-publication-in-medical-journal-highlighting-the-esta68aed23278f45.png https://anavex.com/news/anavex-life-sciences-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-2025/ 2025-12-08T19:51:48+00:00 https://anavex.com/wp-content/uploads/2025/09/1537-anavex-life-sciences-to-present-at-the-hc-wainwright-27th-annual-global-investment-co68b70f8b987bf.png https://anavex.com/news/anavex-life-sciences-announces-oral-blarcamesine-cognitive-resilience-results-approximating-normal-aging-in-new-precision-medicine-clinical-data-from-phase-iib-iii-alzheimers-disease-trial/ 2025-12-08T19:55:55+00:00 https://anavex.com/wp-content/uploads/2025/09/1539-anavex-life-sciences-announces-oral-blarcamesine-cognitive-resilience-results-approxi68c0f2cd9b752.png https://anavex.com/wp-content/uploads/2025/09/191fc6_7253d913f691444aa3c971b83f366c95mv2.avif https://anavex.com/news/anavex-life-sciences-announces-publication-of-oral-blarcamesine-describing-a-new-class-of-clinical-precision-medicine-from-phase-iib-iii-alzheimers-disease-trial/ 2025-12-08T19:57:37+00:00 https://anavex.com/wp-content/uploads/2025/09/1541-anavex-life-sciences-announces-publication-of-oral-blarcamesine-describing-a-new-clas68dc6a1e932d8.png https://anavex.com/wp-content/uploads/2025/09/191fc6_6443b7493d074357a138618641648111mv2.avif https://anavex.com/news/anavex-life-sciences-announces-positive-topline-results-from-phase-2-study-of-anavex3-71-for-the-treatment-of-schizophrenia/ 2025-12-08T19:59:33+00:00 https://anavex.com/wp-content/uploads/2025/10/1545-anavex-life-sciences-announces-positive-topline-results-from-phase-2-study-of-anavex368df19f897297.png https://anavex.com/wp-content/uploads/2025/10/850d88_90b29d125d584ceb858ddca873de7245mv2.avif https://anavex.com/news/anavex-life-sciences-announces-successful-development-of-once-daily-oral-tablet-formulation-for-the-anavex3-71-program/ 2025-12-08T20:00:48+00:00 https://anavex.com/wp-content/uploads/2025/10/1543-anavex-life-sciences-announces-successful-development-of-once-daily-oral-tablet-formu68df19f7d3e51.png https://anavex.com/news/anavex-life-sciences-announces-presentation-at-the-35th-alzheimer-europe-conference-connecting-science-and-communities-the-future-of-dementia-care/ 2025-12-08T20:01:50+00:00 https://anavex.com/wp-content/uploads/2025/10/1547-anavex-life-sciences-announces-presentation-at-the-35th-alzheimer-europe-conference-c68ea1d5a47121.png https://anavex.com/news/anavex-life-sciences-announces-continued-long-term-benefit-from-oral-blarcamesine-compared-to-decline-observed-in-the-alzheimers-disease-neuroimaging-initiative-adni-control-group/ 2025-12-08T20:03:59+00:00 https://anavex.com/wp-content/uploads/2025/10/1549-anavex-life-sciences-announces-continued-long-term-benefit-from-oral-blarcamesine-com6902dce778ca6.png https://anavex.com/wp-content/uploads/2025/10/191fc6_f6b35c8707c44aedaa8029a4c6c5e5c5mv2.avif https://anavex.com/news/anavex-life-sciences-provides-regulatory-update-on-blarcamesine-for-early-alzheimers-disease/ 2025-12-08T20:05:09+00:00 https://anavex.com/wp-content/uploads/2025/11/1551-anavex-life-sciences-provides-regulatory-update-on-blarcamesine-for-early-alzheimers-disease.png https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2025-fourth-quarter-financial-results-on-tuesday-november-25-2025/ 2025-12-08T20:06:15+00:00 https://anavex.com/wp-content/uploads/2025/11/1553-anavex-life-sciences-to-announce-fiscal-2025-fourth-quarter-financial-results-on-tues691c927ba18f8.png https://anavex.com/news/anavex-life-sciences-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference/ 2025-12-08T20:10:14+00:00 https://anavex.com/wp-content/uploads/2025/11/1555-anavex-life-sciences-to-present-at-the-44th-annual-jp-morgan-healthcare-conference.png https://anavex.com/news/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-business-update/ 2025-12-08T20:13:20+00:00 https://anavex.com/wp-content/uploads/2025/11/1557-anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provide692675e4322d7.png https://anavex.com/wp-content/uploads/2025/11/191fc6_01f71ba9aa0c4e0ebe9ed5375eea5637mv2.webp https://anavex.com/wp-content/uploads/2025/11/191fc6_40704c0b5f934cd5ab88e65c70fa8228mv2.webp https://anavex.com/wp-content/uploads/2025/11/191fc6_f26d3930fa1c44a3873d389fd3ba953cmv2.webp https://anavex.com/news/anavex-life-sciences-to-present-oral-blarcamesine-data-at-the-18th-clinical-trials-on-alzheimers-disease-ctad-conference/ 2025-12-08T20:14:35+00:00 https://anavex.com/wp-content/uploads/2025/11/1559-anavex-life-sciences-to-present-oral-blarcamesine-data-at-the-18th-clinical-trials-on6927d576c01b4.png https://anavex.com/news/anavex-life-sciences-announces-new-publication-in-medical-journal-blarcamesine-prevented-cognitive-impairment-in-animal-model-of-alzheimers-disease/ 2025-12-08T20:35:05+00:00 https://anavex.com/wp-content/uploads/2025/08/1533-anavex-life-sciences-announces-new-publication-in-medical-journal-blarcamesine-preven68a67dd23dee4.png https://anavex.com/news/anavex-joins-access-ad-a-major-initiative-funded-by-the-european-commission-through-the-clinical-evaluation-of-blarcamesine-as-part-of-a-precision-medicine-approach-in-alzheimers-disease/ 2026-01-15T22:31:20+00:00 https://anavex.com/wp-content/uploads/2026/01/2043-anavex-joins-access-ad-a-major-initiative-funded-by-the-european-commission-through-t6966bb90b7d55.png https://anavex.com/news/anavex-life-sciences-appoints-senior-vice-president-global-head-of-neurology/ 2026-01-15T22:33:24+00:00 https://anavex.com/wp-content/uploads/2026/01/1852-anavex-life-sciences-appoints-senior-vice-president-global-head-of-neurology.png https://anavex.com/news/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program/ 2026-01-15T22:34:42+00:00 https://anavex.com/wp-content/uploads/2026/01/1839-anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program.png https://anavex.com/news/anavex-life-sciences-submitted-request-for-ema-to-re-examine-its-opinion/ 2026-01-15T22:39:13+00:00 https://anavex.com/wp-content/uploads/2025/12/1689-anavex-life-sciences-submitted-request-for-ema-to-re-examine-its-opinion.png https://anavex.com/news/anavex-life-sciences-provides-update-on-regulatory-review-in-the-eu-for-blarcamesine-to-treat-early-alzheimers-disease/ 2026-01-15T22:40:35+00:00 https://anavex.com/wp-content/uploads/2025/12/1687-anavex-life-sciences-provides-update-on-regulatory-review-in-the-eu-for-blarcamesine-693db256300ba.png https://anavex.com/news/anavex-life-sciences-q1-2026-financial-results/ 2026-02-09T07:25:25+00:00 https://anavex.com/wp-content/uploads/2026/02/Anavex-Q1-2026.webp https://anavex.com/wp-content/uploads/2026/02/Anavex-Condensed-Consolidated-Interim-Statements-of-Operations-and-Comprehensive-Loss.webp https://anavex.com/wp-content/uploads/2026/02/Anavex-Condensed-Consolidated-Interim-Balance-Sheets.webp https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2026-first-quarter-financial-results-on-monday-february-9-2026/ 2026-02-09T14:16:16+00:00 https://anavex.com/wp-content/uploads/2026/02/2738-anavex-life-sciences-to-announce-fiscal-2026-first-quarter-financial-results-on-monda6982f112058c3.png https://anavex.com/news/anavex-life-sciences-appoints-dr-axel-paeger-board-of-directors/ 2026-02-23T12:36:43+00:00 https://anavex.com/wp-content/uploads/2026/02/Anavex-Leadership-and-Neuroscience-Network-Illustration.webp https://anavex.com/news/anavex-presents-td-cowen-health-care-conference-2026/ 2026-02-25T12:07:28+00:00 https://anavex.com/wp-content/uploads/2026/02/anavex-td-cowen-health-care-conference-2026.webp https://anavex.com/news/anavex-life-sciences-to-present-at-the-citizens-life-sciences-conference/ 2026-03-03T12:30:05+00:00 https://anavex.com/news/anavex-blarcamesine-parkinsons-adpd-2026/ 2026-03-17T11:31:00+00:00 https://anavex.com/wp-content/uploads/2026/03/Anavex-Presents-Significant-Blarcamesine-Treatment-Effects-in-Advanced-Alpha-Synuclein-Parkinsons-Disease-Model-at-ADPD-2026.webp https://anavex.com/news/anavex-blarcamesine-autophagy-alzheimers/ 2026-03-20T11:25:13+00:00 https://anavex.com/wp-content/uploads/2026/03/anavex-blarcamesine-autophagy-alzheimers-2026.webp https://anavex.com/news/anavex-blarcamesine-brain-volume-alzheimers-adpd-2026/ 2026-03-23T11:29:06+00:00 https://anavex.com/wp-content/uploads/2026/03/anavex-blarcamesine-brain-volume-alzheimers-adpd-2026.webp https://anavex.com/news/anavex-blarcamesine-eu-regulatory-update-alzheimers/ 2026-03-25T11:25:23+00:00 https://anavex.com/wp-content/uploads/2026/03/Anavex-Blarcamesine-EU-Regulatory-Update-Alzheimers-2026.webp https://anavex.com/news/anavex-regulatory-update-blarcamesine-alzheimers/ 2026-03-30T11:25:43+00:00 https://anavex.com/wp-content/uploads/2026/03/anavex-blarcamesine-regulatory-update-fda-ema-2026.webp https://anavex.com/news/anavex-needham-healthcare-conference-2026/ 2026-04-07T11:25:42+00:00 https://anavex.com/wp-content/uploads/2026/04/Anavex-Needham-Healthcare-Conference-2026.webp